Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

Inclusion Criteria:

   - This study is intended for patients with relapsed and/or refractory multiple myeloma,
   who have received at least one prior line of therapy. Patients must require
   retreatment as per IMWG definitions (Kyle et al 2003). Approximately 50-100 patients
   are expected to be enrolled into this trial.

   - Patient has a previous diagnosis of multiple myeloma, based on IMWG 2003 definitions
   all three of the following criteria had been met:

   - Monoclonal immunoglobulin (M component) on electrophoresis, and on immunofixation on
   serum or on total 24 hour urine (or demonstration of M protein in cytoplasm of plasma
   cell for non secretory myeloma).

   - Bone marrow (clonal) plasma cells ≥ 10% or biopsy proven plasmacytoma

   - Related organ or tissue impairment (CRAB symptoms: anemia, hypercalcemia, lytic bone
   lesions, renal insufficiency, hyperviscosity, amyloidosis or recurrent infections)

   - Patients who have received allogeneic stem cell transplant and do not have active
   graft vs host disease requiring immunosuppressive therapy are eligible.

   - Patient with multiple myeloma (per IMWG 2003 definition) that is relapsed and/or
   refractory to at least one prior line of therapy and requires retreatment

   - Relapsed-and-refractory to a therapy, provided that the patient meets any of the
   following conditions:

   - Relapsed, defined by disease that recurred in a patient that responded under a prior
   therapy, by reaching a MR or better, and had not progressed under this therapy nor up
   to 60 days of last dose of this therapy. Patients who previously responded to
   treatment with BTZ are eligible.

   - Patient has relapsed to at least one prior line and patient was refractory to at least
   one prior line by either not reaching a MR, or progressed while under this therapy, or
   within 60 days of its last dose. Patients previously refractory to BTZ are also
   eligible.

   - Patients with primary refractory disease are eligible.

   - Patients who have previously received high dose therapy/autologous stem cell
   transplant are eligible

   - Patients who have received allogeneic stem cell transplant and do not have active
   graft vs host disease requiring immunosuppressive therapy are eligible

Exclusion Criteria:

   - Patient has shown intolerance to bortezomib, dexamethasone or panobinostat or has any
   contraindications to any of these therapies. following available prescribing
   information

   - Allogeneic stem cell transplant recipient presenting with graft versus host disease
   either active or requiring immunosuppression

   - Patient has grade ≥ 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain
   on clinical examination within 14 days of treatment

   - Patient taking any anti-cancer therapy concomitantly

   - Patient has second primary malignancy < 3 years of first dose of study treatment
   (except for treated basal or squamous cell carcinoma, or in situ cancer of the cervix)